Prostate cancer has one of the strongest genetic components of any common cancer. Up to 60% of prostate cancer risk is driven by inherited factors, making genetics a major piece of the puzzle for any man evaluating his personal risk. That doesn’t mean 60% of cases are caused by a single inherited gene, though. The genetic picture involves everything from rare, high-impact mutations passed down in families to common genetic variations that each nudge risk up by a small amount.
How Family History Shapes Your Risk
The simplest way to gauge genetic risk is through family history. Having one brother with prostate cancer roughly triples your risk compared to a man with no affected relatives. Two brothers with the disease push that to nearly eight times the average risk. Three affected brothers raise it further, to about 18 times the baseline. When a father and one brother are both affected, the risk is about five and a half times higher than normal.
Age matters here too. These risk multipliers are strongest for men under 65. A man younger than 65 with three affected brothers faces a risk roughly 23 times higher than average. For men diagnosed between 65 and 74 with only an affected father, the increase is much more modest, around 1.8 times. In practical terms, a strong family history of prostate cancer at younger ages is a more powerful signal than a relative diagnosed later in life.
Inherited Gene Mutations That Raise Risk
Some families carry specific gene mutations that substantially increase prostate cancer risk. The most well-known are BRCA1 and BRCA2, the same genes linked to breast and ovarian cancer in women. Men with a harmful BRCA2 change face a 19% to 61% chance of developing prostate cancer by age 80, compared to about 10.6% in the general population. BRCA1 carriers have a somewhat lower but still elevated risk, ranging from 7% to 26% by age 80. BRCA2-linked prostate cancers also tend to be more aggressive, more likely to spread, and diagnosed at younger ages.
Another gene worth knowing about is HOXB13. A specific variant called G84E increases prostate cancer risk nearly fivefold. This mutation is less common than BRCA changes but is significant enough that researchers have recommended genetic testing for men in their thirties and forties who carry it, well before typical screening age.
Lynch syndrome, caused by mutations in DNA repair genes (most commonly MSH2 and MSH6), is better known for raising colorectal cancer risk. But men with Lynch syndrome also face nearly five times the expected rate of prostate cancer. In one study tracking 188 men with Lynch syndrome, 11 developed prostate cancer during the follow-up period, compared to the 2.26 cases that would have been expected statistically.
Inherited Mutations vs. Tumor Mutations
There’s an important distinction between two types of genetic changes in prostate cancer. Germline mutations are inherited from a parent, present in every cell of your body from birth, and can be passed to your children. These are the mutations that make prostate cancer “run in families.” Somatic mutations, on the other hand, develop only in the tumor cells over a person’s lifetime. They aren’t inherited and can’t be passed down.
Both types matter clinically. Germline testing tells you (and your family members) about inherited risk. Tumor-specific somatic testing helps oncologists choose the most effective treatments if cancer develops. A man with no family history can still have somatic mutations in his tumor that open the door to targeted therapies, while a man with a known germline mutation may benefit from earlier, more intensive screening.
Genetics and Racial Disparities
African American men are diagnosed with prostate cancer at higher rates and tend to develop more aggressive forms of the disease. Genetics plays a role in this disparity, though it’s intertwined with differences in access to care and other factors. Research into the specific genetic drivers is still catching up. Studies of African American men with early-onset prostate cancer have identified rare mutations in several key genes, including BRCA2, BRIP1, BRCA1, PMS2, and ATM. Some of these are protein-truncating mutations, meaning they completely disable the gene’s protective function, while others are rare missense variants predicted to be harmful.
The challenge is that most large genetic studies have historically underrepresented African American men, so the full spectrum of genetic risk factors in this population is still being mapped. What’s clear is that family history and genetic testing are especially important tools for Black men assessing their prostate cancer risk.
How Genetic Testing Affects Treatment
Knowing your genetic status isn’t just about predicting risk. It can directly change how advanced prostate cancer is treated. Men whose tumors carry mutations in DNA repair genes, particularly BRCA1, BRCA2, and ATM, may respond to a class of targeted drugs called PARP inhibitors. These drugs exploit a weakness in cancer cells that can’t properly repair their own DNA, causing them to die while leaving healthy cells largely unharmed.
The FDA has approved PARP inhibitors for men with metastatic prostate cancer that has stopped responding to standard hormone-blocking treatments, provided their tumors carry qualifying mutations. The list of qualifying genes extends beyond BRCA to include ATM, CHEK2, PALB2, BRIP1, and several others involved in DNA repair. Men with Lynch syndrome-related mutations (causing a condition called microsatellite instability in the tumor) may also respond to immunotherapy drugs that are ineffective in most other prostate cancers.
This is why genetic counselors and oncologists increasingly recommend germline testing for men with aggressive or metastatic prostate cancer, and for men with a strong family history of the disease. The results can shape screening timelines, inform relatives about their own risk, and unlock treatment options that wouldn’t otherwise be considered.
What “Highly Heritable” Actually Means
When researchers say prostate cancer heritability is around 57%, they’re not saying that most cases are caused by a single inherited mutation. Heritability is a population-level statistic. It means that when you look across large groups, more than half the variation in who gets prostate cancer and who doesn’t can be traced to genetic differences rather than lifestyle or environmental factors. Most of that genetic influence comes not from rare high-risk mutations like BRCA2, but from hundreds of common genetic variants that each contribute a tiny amount of risk. On their own, none of these common variants are meaningful. Together, they add up.
Researchers are working to combine these small-effect variants into polygenic risk scores, essentially a single number that captures your cumulative genetic risk based on many gene regions at once. The goal is to use these scores to personalize screening, so that men at higher genetic risk start screening earlier or more frequently, while men at lower risk can avoid unnecessary tests. This approach isn’t yet standard practice, but it’s moving closer to clinical use.